Biotech Startups

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way. The company works on genetic medicine, aiming to address limitations in delivery, safety, durability, and cost.

6 investors

SOPHiA GENETICS develops the SOPHiA DDM data analytics platform for genomic and multimodal data analysis, offering solutions used in oncology research and in vitro diagnostics. Its products serve clinical and research institutions, with several CE-IVD diagnostic solutions available across Europe, the UK, Switzerland, and Israel.

6 investors

Stämm is a biomanufacturing company founded in 2016 that builds the Bioprocessor, a continuous, bubble-free bioreactor using single-use 3D-printed cartridges for producing monoclonal antibodies, biosimilars, and cell and gene therapies. It serves biologics producers seeking lower costs and scalable, automated manufacturing.

6 investors

Starling Medical develops smart devices and predictive learning solutions focused on preventative bladder health and urinary tract infection management. The company combines digital health technology with clinical analytics to augment standard UTI care.

6 investors

Strand is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancers and autoimmune diseases. The company has created an mRNA platform with cell-selective targeting capabilities to deliver therapeutic payloads within the body.

6 investors

Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies. Its algorithms combine measures such as tumor mutation burden and gene expression to help match patients to the most suitable therapy.

6 investors

Strategikon Pharma develops Clinical Maestro, a software platform for managing clinical business operations including budgeting, sourcing, contracting, and vendor management, with AI-driven cost benchmarking tools. It serves biopharmaceutical companies of all sizes and Clinical Research Organizations (CROs) involved in clinical trial outsourcing.

6 investors

Synteny develops an AI platform that models the rules of molecular recognition to design modular protein therapeutics, pairing generative biology models with high-throughput experimental validation. The company is building a pipeline of T cell receptor T cell engager (TCR TCE) therapeutics targeting intracellular proteins for solid tumour oncology and cell-specific depletion in immunology.

6 investors

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy. Its pipeline targets cancer and inflammatory diseases.

6 investors

Clinical-stage biotech expanding the genetic alphabet with synthetic nucleotides; acquired by Sanofi for $2.5B in 2020.

6 investors

Syntis Bio develops oral therapies that use the biology of the small intestine to treat conditions ranging from rare genetic disorders to common diseases. The company is advancing a pipeline of drug candidates across multiple therapeutic areas, beginning with obesity.

6 investors

Tacit Therapeutics develops RNA-based gene therapy approaches by redirecting cellular splicing processes to repair mutated genes. The company serves patients with genetic diseases and is based in San Francisco.

6 investors

Offers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.

6 investors

Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications. Its pipeline includes a dual-target CD19/BCMA CAR structure and a CD7-targeted mRNA lipid nanoparticle CAR-T delivery platform, with lead candidate TPST-4003 planned for trials in myasthenia gravis and multiple sclerosis.

6 investors

Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets. It runs an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases.

6 investors

Tmunity Therapeutics was a University of Pennsylvania spinout developing engineered T-cell therapies, including CAR-T and TCR-based treatments, for cancers.

6 investors

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer. The company applies a target-first molecular glue discovery platform to pursue disease targets previously considered undruggable.

6 investors

TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation. The company runs clinical studies across Europe and the US targeting structural heart institutions and cardiac patients.

6 investors

Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system. Its lead program, TGX-007, is a gene therapy for glioblastoma in a Phase I/II clinical trial, with potential applications in solid tumours and regenerative medicine.

6 investors

Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument. It targets routine blood testing for consumers as an alternative to traditional off-site labs, pursuing a staged FDA clearance strategy for its assays.

6 investors

A company focused on developing clinical treatments aimed at improving patient outcomes.

6 investors

uniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.

6 investors

Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.

6 investors

A biopharmaceutical company developing medicines and vaccines with a focus on clinical research and development for human health.

6 investors